<DOC>
	<DOCNO>NCT02118285</DOCNO>
	<brief_summary>This single center phase I trial design determine maximum tolerate dose ( MTD ) oral IDO inhibitor INCB024360 administer part large regimen intraperitoneal ( IP ) delivery haploidentical donor NK cell IL-2 non-myeloablative cyclophosphamide/fludarabine ( Cy/Flu ) preparative regimen treatment recurrent ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Intraperitoneal Natural Killer Cells INCB024360 Recurrent Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>Haploidentical donor NK cell 1st dose IL-2 infuse intraperitoneally ( IP ) non-myeloablative preparative regimen cyclophosphamide fludarabine . IP IL-2 continue three time week 5 additional dos . INCB024360 , assign dose , begin 2 day NK cell infusion ( day -2 ) continue twice daily 90 day . Follow-up disease response survival 1 year NK cell infusion possibility re-treatment patient experience least clinical benefit minimum 6 month prior disease progression . The MTD INCB024360 determine use continual reassessment method ( CRM ) . The 1st 2 patient enrol dose level 1 ( 50 mg bid ) INCB024360 . Each new cohort 2 patient sequentially assign appropriate dose study statistician base updated toxicity profile . Up 4 dose level INCB024360 test ( 50 , 100 , 200 , 300 mg bid ) dose level -1 ( 25 mg bid ) use event 50 mg bid prove toxic . The MTD identify total sample size 20 patient exhaust .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Diagnosis recurrent epithelial ovarian cancer , fallopian tube , primary peritoneal cancer fail progress least 1 prior salvage chemotherapy regimen direct recurrent/metastatic disease . Measurable disease per disease specific RECIST version 1.1 patient bone site disease eligible If history brain metastasis must stable least 3 month treatment A brain CT scan require subject know brain metastasis time enrollment subject clinical sign symptom suggestive brain metastasis . Available related HLAhaploidentical NK cell donor least Class I serologic type A &amp; B locus Age 18 year old GOG Performance Status ≥ 2 refer appendix III Adequate organ function determine follow criterion within 14 day start preparative regimen , unless otherwise note : Bone marrow : platelet ≥ 80,000 x 109/L hemoglobin ≥ 9 g/dL , unsupported transfusion ; absolute neutrophil count ( ANC ) ≥ 1000 x 109/L , unsupported GCSF granulocytes Renal function : estimate glomerular filtration rate ( GFR ) ≥ 50 ml/min ( base Fairview Laboratories formula time screen ) Liver function : total bilirubin &lt; 1.5 time upper limit institutional normal ; AST , ALT , alkaline phosphatase &lt; 3 time upper limit institutional normal Cardiac : Left ventricular ejection fraction &gt; 40 % ( within 28 day treatment start ) Pulmonary function : &gt; 50 % correct DLCO FEV1 , presence pleural effusion due metastatic disease &gt; 40 % correct DLCO FEV1 acceptable ( within 28 day treatment start ) Able prednisone immunosuppressive medication prescribe per protocol least 3 day prior Day 0 At least 14 day must lapse last prior anticancer treatment 1st day preparative regimen Not pregnant lactate The agent use study may teratogenic fetus information excretion agent breast milk . Participants childbearing potential must blood test urine study within 14 day prior registration rule pregnancy agree use adequate birth control study treatment . Able tolerate intraperitoneal ( IP ) port placement IP treatment administration opinion enrol investigator Voluntary write consent Active infection must afebrile antibiotic Receiving monoamine oxidase inhibitor ( MAOI ) drug significant MAOI activity ( meperidine , linezolid , methylene blue ) within 21 day 1st dose fludarabine Requiring potent CYP3A4 inducer inhibitor Have ever Serotonin Syndrome receive one serotonergic drug Prior therapy antiCTLA4 antibody , anti PD1 , experimental immune systemtargeted therapy Use UGT1A9 inhibitor include : diclofenac , imipramine , ketoconazole , mefenamic acid , probenecid screen followup period . Undergone organ transplant ( ) include allogeneic stem cell bone marrow transplant . Unstable cardiovascular disease ( eg , uncontrolled hypertension , peripheral vascular disease , congestive heart failure , cardiac arrhythmia , acute coronary syndrome ) within 6 month start study treatment . Any gastrointestinal condition cause malabsorption obstruction ( eg , celiac sprue , gastric bypass surgery , stricture , adhesion , history small bowel resection , blind loop syndrome ) . Unable unwilling swallow tablet BID . Active autoimmune process ( eg rheumatoid arthritis , moderate severe psoriasis , multiple sclerosis , inflammatory bowel disease , etc . ) receive therapy autoimmune inflammatory disease . Vitiligo , thyroiditis , eczema permit patient otherwise eligible Known HIVpositivity History hepatitis positive serology follow : Hepatitis B ( HepB ) screen test require : HepB SAg ( hepatitis B surface antigen ) ; AntiHepB SAg ( antibody hepatitis B surface antigen ) ; AntiHepatitis B core IgG ( antibody hepatitis B core antigen ) . Hepatitis B core IgM antibody Hepatitis C screen test require : HCVantibody ( antibody hepatitis C virus ) ; HCVRNA ( serum test circulate virus , base detect RNA )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Fallopian cancer</keyword>
	<keyword>Primary peritoneal cancer</keyword>
</DOC>